English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe U.S. Food and Drug Administration (FDA) recently granted approval to Lecanemab, the first Alzheimer’s disease treatment to win approval since the largely failed rollout of Aduhelm two years ago.
Tag: Aduhelm
MEDIA ADVISORY: Cedars-Sinai Experts On Hand to Discuss New Alzheimer’s Drug Now Under Review
The U.S. Food and Drug Administration is poised to make a decision on another new Alzheimer’s disease treatment this week, and experts from the Jona Goldrich Center for Alzheimer’s and Memory Disorders at Cedars-Sinai are available to explain how the drug works and which patients could benefit from the medication.
Is everything we think we know about Alzheimer’s wrong?
Beta-amyloid is far from the only factor in dementia, memory loss and Alzheimer’s disease, and far from the only target for drugs, says the director of a top Alzheimer’s center. Research on many molecules, and an emphasis on preventing or slowing the disease, are both crucial.
Fixed vial sizes for controversial Alzheimer’s drug could waste $605 million in Medicare spending each year
Medicare could waste up to $605 million per year on the controversial Alzheimer’s drug aducanumab if it is eventually approved for widespread use because it is supplied in vials containing fixed doses that may not be appropriate for all patients–resulting in the trashing of large volumes of unused drug
UNLV Alzheimer’s Researcher and Expert Panel Present First-Use Recommendations For Aducanumab
A group of six leading Alzheimer’s experts has convened to make the first recommendations for the appropriate use of aducanumab (Aduhelm, Biogen/Eisai), a newly approved treatment for early Alzheimer’s disease. The recommendations will help provide clinicians with greater clarity and…
Ensuring Timely, Appropriate And Equitable Access To Aduhelm
Aduhelm has been approved for use for those with Mild Cognitive Impairment or early stage Alzheimer’s dementia. This treatment offers a marginal but potentially meaningful slowing of decline for this subpopulation of individuals with Alzheimer’s disease, a terminal disease with no survivors. Though approved, access to the treatment is at risk of being impeded by significant barriers which may further deepen issues of health equity.